Initial phase III trial results from November 2020 suggested that, after two doses, new mRNA vaccines developed by Moderna ...

Dr. Kaushal's vaccine candidate is called delta sigmaH—he has modified the bacterium by deleting the gene needed to make a protein called sigmaH (sigH). Without sigH, the bacterium is unable to ...

But the vaccines were, and still are ... from a household member who had an infection caused by SARS-CoV-2’s delta variant (Lancet Infect. Dis. 2021, DOI: 10.1016 /S1473-3099(21)00648-4).